As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ERROR 2

Yes! I want to get the latest chemistry news from C&EN in my inbox every week.

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Vertex Pharmaceuticals is moving beyond its cystic fibrosis small-molecule franchise. The company is purchasing the Cambridge, Massachusetts–based start-up Semma Therapeutics, which is designing stem cell therapies for type 1 diabetes, for $950 million in cash. Semma has a method for turning stem cells into insulin-secreting β cells, which it licensed from Harvard University’s Douglas Melton. The company plans to start clinical trials of its β cell injections next year.